Atlas Trials

Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL

Clinical trial NCT07415980 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07415980
Sponsor
Sun Yat-sen University
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Double Expressor DLBCL
Start date
2026-04-01
Primary completion
2028-04-01
Enrollment
68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.